TABLE 1.
Clinical outcomes for sustained responders and late failures over the first 12 months of mepolizumab treatment
| Sustained responders | Late failures | |||||||
| n | Baseline | 12 months | p-value | n | Baseline | 12 months | p-value | |
| ACQ | 34 | 2.75 (1.81–4.04) | 2.00 (0.83–3.51) | 0.003 | 13 | 3.83 (2.95–5.08) | 3.00 (2.41–4.40) | 0.173 |
| AQLQ | 31 | 3.40 (2.20–4.06) | 4.73 (3.80–6.20) | <0.001 | 11 | 2.07 (1.70–3.80) | 3.53 (3.06–4.73) | 0.033 |
| FEV1 % pred | 32 | 73.5 (64.5–85.2) | 78.5 (64.0–95.3) | 0.651 | 10 | 77.0 (59.5–87.3) | 67.5 (57.5–84.3) | 0.168 |
| FeNO ppb | 28 | 21.0 (10.3–36.5) | 24.0 (9.0–40.8) | 0.476 | 12 | 34.5 (16.0–58.3) | 29 (16.8–85.3) | 0.505 |
| Blood eosinophils ×109 cells·L−1 | 34 | 0.20 (0.07–0.33) | 0.04 (0.02–0.07) | <0.001 | 10 | 0.26 (0.11–0.59) | 0.06 (0.03–0.13) | 0.008 |
| Exacerbations per year | 26 | 4.0 (0.0–5.3) | 1.0 (0.0–1.3) | 0.006 | 8 | 1.0 (0.0–4.0) | 1.5 (0.3–2.8) | 0.799 |
| Prednisolone dose mg per day | 35 | 10 (5–20) | 5 (0–6) | <0.001 | 13 | 10 (3–20) | 4 (1–11) | 0.008 |
| Adherence % pickup | 22 | 80 (80–100) | 90 (79–100) | 0.876 | 10 | 80 (80–85) | 80 (80–100) | 0.705 |
Data are presented as median (interquartile range), unless otherwise stated. Significance level (p-value) in change versus baseline by Wilcoxon signed rank test. ACQ: asthma control questionnaire; AQLQ: asthma quality of life questionnaire; FEV1: forced expiratory volume in 1 s; FeNO: fractional expired nitric oxide. Baseline blood eosinophils in the table were measured at initiation of treatment, and therefore were not the same as those in the decision for approval of biologic therapy.